Stock Trim Losses -...
Health Care: Drugs
Transition Therapeutics Inc. (TTHI: NASDAQ)
$3.06 0.03 | 0.99%
05/23/13 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 3.03 |
| 52 Week High | 3.84 |
| 52 Week Low | 1.78 |
| Avg. Daily Vol. (Mil) | 0.07 |
| Beta (3 year) | 0.41 |
| Share Related Items | |
| Mkt Cap (Mil) | 81.57 |
| Shares Out (Mil) | 26.92 |
| Float (Mil) | 13.89 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 7.10 |
| Current Ratio | 7.20 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.00 |
| Valuation Ratios | |
| Price Earnings | 588.10 |
| Price/Sales | 7.40 |
| Price/Book | 2.37 |
| Price/Cash Flow | 47.70 |
| Per Share Data | |
| Earnings | 0.01 |
| Sales | 0.41 |
| Book Value | 1.28 |
| Cash Flow | 0.06 |
| Business Summary | |
|---|---|
| Transition Therapeutics Inc. is a product-focused biopharmaceutical company, developing therapeutics for disease indications with large markets. | |
| General Information | |
| 101 College Street
Suite 220 Toronto, ON M5G 1L7 |
|
| www.transitiontherapeutics.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 16 | |
| CEO: Dr. Tony F. Cruz | |
| Short Interest | |
| Current Month (Mil) | 0.01 |
| Previous Month (Mil) | 0.01 |
| Short Interest Ratio (Days) | 0.10 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -0.20 |
| Return on Investments | -0.20 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | 7.80 |
| Profit Margin | -0.60 |
Portfolios with TTHI
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks With Big Insider Buy...
- UserThe 1000 Club
- UserBiotech for Obama Presidency
- ContributorStockerblog.com Canadian Li...
- UserPhels
Latest TTHI Headlines from TheStreet
- 5 Stocks Under $5 Making Big Moves 09.20.12 | 02:09 pm
- 7 Stocks Under $10 With Relative Strength 07.06.12 | 02:07 pm
- 5 Stocks With Huge Insider Buying 12.01.11 | 06:12 am
- Transition Therapeutics Inc. Stock Downgraded (TTHI) 05.23.11 | 08:05 am
- Transition Stock Gaps Up On Today's Open (TTHI) 03.21.11 | 09:03 am
- Transition Therapeutics Inc.: News Release 02.22.11 | 11:02 am
- Transition Stock Soars Higher (TTHI) 02.22.11 | 10:02 am
- Transition Therapeutics Inc. Stock Upgraded By TheStreet Ratings (TTHI) 02.09.11 | 05:02 pm
- Transition Therapeutics Announces Second Quarter Fiscal 2011 Financial Results 02.07.11 | 04:02 pm
- Transition Therapeutics To Hold Conference Call On Second Quarter Fiscal 2011 Financial Results On Monday, February 7th, At 4:30 P.M. EST 02.04.11 | 01:02 pm
Press Releases for TTHI
- Transition Therapeutics To Hold Conference Call On Second Quarter Fiscal 2013 Financial Results On Thursday, February 7th, At 4:30 P.M. EST - PR Newswire 02.04.13 | 12:02 pm
- Transition Therapeutics Announces Enrollment Of The First Patient In Phase 2 Study Of ELND005 (Scyllo-inositol) For The Treatment Of Agitation/Aggression In Patients With Alzheimer's Disease - PR Newswire 11.28.12 | 08:11 am
- Transition Therapeutics To Hold Conference Call On First Quarter Fiscal 2013 Financial Results On Thursday, November 8th, At 4:30 P.M. EST - PR Newswire 11.05.12 | 04:11 pm
- Transition Therapeutics To Hold Conference Call On Full Year Fiscal 2012 Financial Results On Thursday, September 13th, At 4:30 P.M. EST - PR Newswire 09.11.12 | 04:09 pm
- Transition Therapeutics Announces Dosing Of First Patient In Phase 2 Clinical Study Of ELND005 In Bipolar Disorder - PR Newswire 08.30.12 | 07:08 am
- Transition Therapeutics To Present At The Canaccord Genuity Annual Growth Conference - PR Newswire 08.13.12 | 04:08 pm
- LifeSci Advisors Announces Investment Opinion On Transition Therapeutics, Inc. - Business Wire 06.16.11 | 09:06 am
- Elan And Transition Therapeutics Announce Topline Summary Results Of Phase 2 Study And Plans For Phase 3 For ELND005 (Scyllo-inositol ) - Business Wire 08.09.10 | 04:08 pm
Partner Headlines for TTHI
- Transition Therapeutics To Trade Higher Into Upcoming Trial Results For Diabetes Drug - Seeking Alpha 01.28.13 | 09:01 am
- Elan Starts Phase II ELND005 Study - Analyst Blog - NASDAQ 09.06.12 | 08:09 pm
- Transition Therapeutics Announces ELND005 Phase 2 Clinical Trial Data to be Presented at the International Conference of Alzheimer's Disease (ICAD) Meeting - Benzinga 07.15.11 | 04:07 pm
- Morning Market Losers - Benzinga 05.31.11 | 10:05 am
- Morning Market Movers (FONR, TTHI, GFN, CEBK) - Benzinga 02.22.11 | 09:02 am
- Life Sciences Companies Raise Record Amounts of Capital - Seeking Alpha 12.31.10 | 04:12 pm
- Elan to Move ELND005 to Phase III - Analyst Blog - Zacks 08.16.10 | 04:08 pm
